Disease · EFO_1001478

systemic inflammatory response syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. systemic inflammatory response syndrome. Diseases, record EFO_1001478. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001478

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: systemic inflammatory response syndrome; Open Targets
Open Targets ID: EFO_1001478; Open Targets
Other names: Inflammatory Response Syndrome, Systemic, SIRS, Sepsis Syndrome; Open Targets
MeSH: D018746; MeSH
NCI Thesaurus: C94832; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 4 of its 18 drugs, from ClinicalTrials.gov; Open Targets

Drugs18

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
INDOMETHACIN	CHEMBL6	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SELENIUM	CHEMBL6068503	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ULINASTATIN	CHEMBL2108163		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ZEGOCRACTIN	CHEMBL4753998	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ATORVASTATIN	CHEMBL1487	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE DIPROPIONATE	CHEMBL1200384	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE SODIUM PHOSPHATE	CHEMBL1200762	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 18

See all 18 drugs

Targets27

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	12	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
GABRA1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2562	Drugs and targets

1 to 10 of 27

See all 27 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04681066	A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS	Phase 2	216	2025-10-16	Acute Pancreatitis, Systemic Inflammatory Response Syndrome	ZEGOCRACTIN	Its record names the disease	ClinicalTrials.gov
NCT02692391	A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis	Phase 3	42	2021-04-22	Acute Pancreatitis	INDOMETHACIN	Its record names the disease	ClinicalTrials.gov
NCT03401190	CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS	Phase 2	21	2021-12-07	Acute Pancreatitis, Systemic Inflammatory Response Syndrome	ZEGOCRACTIN	Its record names the disease	ClinicalTrials.gov
NCT01141556	Effects of High-dose Intravenous Selenium (Selenase®) in Adult Patients Subjected to Elective All-cause Heart Surgery	Phase 3	410		Heart; Surgery, Heart, Functional Disturbance as Result, Self Efficacy	SELENIUM	Its record names the disease	ClinicalTrials.gov
NCT04254744	SIRS in Cyanotic and Acyanotic Children in Cardiac Surgery		197		SIRS, Pediatric Cardiac Surgery	SEVOFLURANE	Its record names the disease	ClinicalTrials.gov
NCT05391789	Clinical Efficacy of Ulinastatin for Treatment of Sepsis With Systemic Inflammatory Response Syndrome	Phase 3	120		Sepsis	ULINASTATIN	Its record names the disease	ClinicalTrials.gov
NCT05946122	Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index	Phase 1	106		Renal Protection	ATORVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT02666703	Extracorporeal Cytokine Adsorption in Cardiac Surgery	Phase 3	60		Cardiopulmonary Bypass	METHYLPREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT04195347	Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase	Phase 1/2	42		Acute Pancreatitis	ZEGOCRACTIN	Its record names the disease	ClinicalTrials.gov
NCT01296074	Corticosteroid Prophylaxis on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response	Not applicable	30		Heart Valve Diseases, Systemic Inflammatory Response Syndrome	METHYLPREDNISOLONE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Indomethacin Suppository vs Placebo: Mortality	0 of 18	1 of 24	42	NCT02692391	Trial comparisons
Indomethacin Suppository vs Placebo: Number of Participants Who Development of Organ Failure	3 of 18	6 of 24	42	NCT02692391	Trial comparisons
Indomethacin Suppository vs Placebo: deaths from any cause	0 of 18	1 of 24	42	NCT02692391	Trial comparisons
Indomethacin Suppository vs Placebo: serious adverse events	0 of 18	0 of 24	42	NCT02692391	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
24513806	RESULT	1	PubMed
15173799	RESULT	1	PubMed
41938843	DERIVED	1	PubMed
34704970	DERIVED	1	PubMed
33939666	DERIVED	1	PubMed
32292492	DERIVED	1	PubMed
30624149	DERIVED	1	PubMed
28502744	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001478

GET https://conductscience.org/api/diseases/v1/EFO_1001478/targets?page=2

API reference For AI assistants